2. Search Result
Search Result
Results for "

cytotoxic+agent

" in MedChemExpress (MCE) Product Catalog:

75

Inhibitors & Agonists

1

Screening Libraries

1

Fluorescent Dyes

2

Biochemical Assay Reagents

3

Peptides

3

Inhibitory Antibodies

20

Natural
Products

1

Isotope-Labeled Compounds

2

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-19609
    Calicheamicin
    Maximum Cited Publications
    11 Publications Verification

    Calicheamicin γ1

    		 DNA Alkylator/Crosslinker ADC Payload Bacterial Apoptosis Antibiotic Infection Cancer
    Calicheamicin, an antitumor antibiotic, is a cytotoxic agent that causes double-strand DNA breaks. Calicheamicin is a DNA synthesis inhibitor .
    Calicheamicin
  • HY-P9985
    Disitamab vedotin
    5 Publications Verification

    RC48

    		 Antibody-Drug Conjugates (ADCs) EGFR Cancer
    Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE) (HY-15162), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Disitamab vedotin enhances antitumor immunity .
    Disitamab vedotin
  • HY-109539
    Gemtuzumab ozogamicin
    1 Publications Verification

    		 Antibody-Drug Conjugates (ADCs) Apoptosis Cancer
    Gemtuzumab ozogamicin is an antibody-drug conjugate (ADC) consisting of a humanized immunoglobulin (IgG4) antibody directed against CD33 that is conjugated to the cytotoxic agent Calicheamicin (HY-19609). The antibody portion is Gemtuzumab (HY-P99971), and the drug-linker conjugate for ADC is N-Ac-γ-Calicheamicin-AcBut-NHS ester (HY-103688). Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia (AML) .
    Gemtuzumab ozogamicin
  • HY-P99107A
    Brentuximab vedotin (solution)
    1 Publications Verification

    		 Antibody-Drug Conjugates (ADCs) Apoptosis Cancer
    Brentuximab vedotin (solution) (cAC10-vcMMAE) is an antibody-drug conjugate (ADC) comprising an anti-CD30 antibody and the cytotoxic agent Monomethyl auristatin E (MMAE). The antibody portion is Brentuximab (HY-P99151), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Brentuximab vedotin (solution) inhibits CD30-positive cells with an IC50 of 2.5 ng/mL. Brentuximab vedotin (solution) can be used for the research of relapsed and refractory Hodgkin lymphoma .
    Brentuximab vedotin (solution)
  • HY-114778
    Fluzoparib
    4 Publications Verification

    SHR3162; Fuzuloparib

    		 PARP Cancer
    Fluzoparib (SHR3162) is a potent and orally active PARP1 inhibitor (IC50=1.46±0.72 nM, a cell-free enzymatic assay) with superior antitumor activity. Fluzoparib selectively inhibits the proliferation of homologous recombination repair (HR)-deficient cells, and sensitizes both HR-deficient and HR-proficient cells to cytotoxic agents. Fluzoparib exhibits good pharmacokinetic properties in vivo and can be used for BRCA1/2-mutant relapsed ovarian cancer research .
    Fluzoparib
  • HY-P99542
    Tusamitamab ravtansine

    SAR-408701; HuMAb2-3-SPDB-DM4

    		 Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin Cancer
    Tusamitamab ravtansine (SAR-408701) is a targeted ADC against tumor cells expressing CEACAM5, composed of a humanized anti-CEACAM5 monoclonal antibody covalently linked to the potent cytotoxic agent, maytansinoid DM4 (HY-12454), via a cleavable linker. Tusamitamab ravtansine has an average drug-to-antibody ratio (DAR) of 3.8 .
    Tusamitamab ravtansine
  • HY-12456
    Duocarmycin SA

    		Antibiotic ADC Payload DNA Alkylator/Crosslinker Necroptosis Apoptosis Cancer
    Duocarmycin SA is an orally active antitumor antibiotic with an IC50 of 10 pM . Duocarmycin SA is an extremely potent cytotoxic agent capable of inducing a sequence-selective alkylation of duplex DNA. Duocarmycin SA demonstrates synergistic cytotoxicity against glioblastoma multiforme (GBM) cells treated with proton radiation in vitro .
    Duocarmycin SA
  • HY-18981
    Decursin
    2 Publications Verification

    (+)-Decursin

    		 PKC Apoptosis CXCR Neurological Disease Inflammation/Immunology Cancer
    Decursin ((+)-Decursin) is a potent anti-tumor agent. Decursin also is a cytotoxic agent and a potent protein kinase C activator. Decursin induces apoptosis and cell cycle arrest at G1 phase. Decursin decreases the expression of CDK2, CDK4, CDK6, cyclin D1 protein at 48 h. Decursin inhibits cell proliferation and migration. Decursin shows anti-tumor, anti-inflammatory and analgesic activities .
    Decursin
  • HY-13640
    Rabacfosadine

    GS-9219; VDC-1101

    		 Nucleoside Antimetabolite/Analog Cancer
    Rabacfosadine (GS-9219), a novel proagent of the nucleotide analogue PMEG, is designed as a cytotoxic agent that preferentially targets lymphoid cells.
    Rabacfosadine
  • HY-111606
    DUPA

    		Ligands for Target Protein for PROTAC Cancer
    DUPA, belongs to a class of glutamate ureas, is used as the targeting moiety in agent conjugate to selectively deliver cytotoxic agents to prostate cancer cells .
    DUPA
  • HY-P99967
    Cantuzumab

    		ADC Antibody Cancer
    Cantuzumab is a monoclonal antibody that can binds the CanAg antigen. Cantuzumab is typically linked to one of several cytotoxic agents, yielding antibody-drug conjugates (ADC), such as Cantuzumab mertansine (HY-P99492) and Cantuzumab ravtansine (HY-P99493) .
    Cantuzumab
  • HY-132257
    Rovalpituzumab tesirine

    SC-002

    		 Antibody-Drug Conjugates (ADCs) Notch Cancer
    Rovalpituzumab tesirine (SC-002) is an antibody-drug conjugate (ADC) with anticancer effects. Rovalpituzumab tesirine contains a DLL3-targeting antibody Rovalpituzumab (HY-P99043) tethered to a cytotoxic agent pyrrolobenzodiazepine by means of a protease-cleavable linker. Rovalpituzumab tesirine can be used for the stduy of small cell lung cancer (SCLC) .
    Rovalpituzumab tesirine
  • HY-132180A
    Seco-DUBA

    		ADC Payload DNA/RNA Synthesis Inflammation/Immunology Cancer
    Seco-DUBA hydrochloride is a DNA-targeting cytotoxic agent. Seco-DUBA hydrochloride binds to the minor groove of A-T-rich DNA regions, alkylates the adenine N3 residue, and undergoes spontaneous spirocyclization to generate active DUBA (HY-160969). Seco-DUBA hydrochloride exerts cytotoxic activity against human cancer cells. The reduced hydrophobicity of Seco-DUBA hydrochloride supports the development of antibody-drug conjugates .
    Seco-DUBA
  • HY-N2123
    Neoliquiritin
    1 Publications Verification

    		 Caspase Neurological Disease Cancer
    Neoliquiritin is a flavonoid and flavanone-derived cytotoxic agent with anticancer activity and neuroprotective effects. Neoliquiritin exhibits excellent tumor specificity, exerting a more pronounced killing effect on cancer cells compared with normal oral cells. Neoliquiritin also exerts neuroprotective effects by inhibiting ATP depletion and the elevation of caspase 3/7 activity. Widely present in the roots of Glycyrrhiza uralensis, Glycyrrhiza inflata and Glycyrrhiza glabra, Neoliquiritin can be applied to studies on human oral squamous cell carcinoma, leukemia, Parkinson's disease and other conditions .
    Neoliquiritin
  • HY-W028690
    DNMDP
    4 Publications Verification

    		 Phosphodiesterase (PDE) Cancer
    DNMDP, a phosphodiesterase 3A (PDE3A) inhibitor, is a potent and selective cancer cell cytotoxic agent. DNMDP binding to PDE3A promotes an interaction between PDE3A and Schlafen 12 (SLFN12). DNMDP shows clear cell-selective cytotoxicity .
    DNMDP
  • HY-141604
    Glembatumumab vedotin
    1 Publications Verification

    CDX-011; CR011-vcMMAE

    		 Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin Cancer
    Glembatumumab vedotin (CDX-011) is an ADC comprising a fully human IgG2 monoclonal antibody (CR011) directed against glycoprotein NMB (GPNMB) and conjugated to the potent tubulinbinding cytotoxic agent MMAE via a protease-sensitive vc linker. Glembatumumab vedotin has potent anticancer effects .
    Glembatumumab vedotin
  • HY-W017424
    2-Aminobenzothiazole

    		Drug Intermediate Caspase Apoptosis Neurological Disease Cancer
    2-Aminobenzothiazole acts as a caspase 3/7 activator, an anticancer cytotoxic agent, and also exhibits neurotoxicity. 2-Aminobenzothiazole drives the apoptotic pathway by activating caspase 3/7, induces mitochondrial inner membrane depolarization, and triggers both early and late apoptosis via a caspase-dependent pathway. In zebrafish models, 2-Aminobenzothiazole induces oxidative damage in brain tissues and inhibits genes related to GABA and 5-HT synthesis pathways. Long-term exposure to 2-Aminobenzothiazole impairs motor ability, social behavior, anxiety-like state and cognitive function. 2-Aminobenzothiazole can be used in studies of human laryngeal carcinoma and related neurotoxicity .
    2-Aminobenzothiazole
  • HY-156712
    Depatuxizumab MMAE

    		Antibody-Drug Conjugates (ADCs) EGFR Cancer
    Depatuxizumab MMAE is an antibody-drug conjugate (ADC) comprising an anti EGFR monoclonal antibody (Depatuxizumab) (HY-P99849) and the cytotoxic agent Monomethyl auristatin E (MMAE) (HY-15162). Depatuxizumab MMAE can be used for the study of EGFR-expressing advanced solid tumors.
    Depatuxizumab MMAE
  • HY-138540
    1-Dodecylimidazole
    3 Publications Verification

    N-Dodecylimidazole

    		 Fungal Cancer
    1-Dodecylimidazole (N-Dodecylimidazole) is a lysosomotropic detergent and a cytotoxic agent. 1-Dodecylimidazole causes cell death by its acid-dependent accumulation in lysosomes, disruption of the lysosomal membrane, and releaseof cysteine proteases into the cytoplasm. 1-Dodecylimidazole has hypocholesterolaemic activity and broad-spectrum antifungal activity .
    1-Dodecylimidazole
  • HY-Y0315
    Hexane-2,5-dione

    2,5-HD

    		 Drug Metabolite Neurological Disease
    Hexane-2,5-dione (2,5-HD) is a cytotoxic agent. Hexane-2,5-dione causes an accumulation of neurofilaments within axons in rats that may lead to their degeneration. Hexane-2,5-dione is promising for research of neurodegenerative diseases (e.g., Alzheimer's, Parkinson's) .
    Hexane-2,5-dione
  • HY-P10239
    Tyr3-Octreotate

    		Somatostatin Receptor Radionuclide-Drug Conjugates (RDCs) Cancer
    Tyr3-Octreotate is a ligand for somatostatin receptor subtype 2 (sst2), with an IC50 value of 1.3 nM against sst2 when labeled with [ 111In-DTPA], and an IC50 value of 1.6 nM against sst2 when labeled with [ 90Y-DOTA]. Radiolabeled Tyr3-Octreotate generates cell-associated radioactivity, and acts as both a tumor growth inhibitor and a tumor cytotoxic agent. When radiolabeled with 177Lu or 90Y, Tyr3-Octreotate serves as a peptide receptor radionuclide therapy (PRRT) analog. Tyr3-Octreotate can be used in studies related to pancreatic tumors .
    Tyr3-Octreotate
  • HY-122751
    (R)-DNMDP

    		Phosphodiesterase (PDE) Cancer
    (R)-DNMDP is a potent and selective cancer cell cytotoxic agent. (R)-DNMDP, the R-form of DNMDP, binds PDE3A directly. (R)-DNMDP has a 500-fold lower EC50 compared to the (S)-enantiomer in HeLa cell line .
    (R)-DNMDP
  • HY-16232
    Glufosfamide

    D 19575; Glucosylifosfamide mustard

    		 Apoptosis Caspase Bcl-2 Family Cancer
    Glufosfamide is a glucose-conjugated alkylating cytotoxic agent and a derivative of Ifosfamide (HY-17419). Glufosfamide induces apoptosis frequency and increase the expression of caspase-9 and caspase-3 in cancer cells. Glufosfamide shows great anti-tumor activity in MiaPaCa-2-RFP mouse model. Glufosfamide can be used for the study of hepatocellular carcinoma, prostate cancer and pancreatic carcinoma .
    Glufosfamide
  • HY-137773
    N-Methyl pemetrexed

    		Drug Metabolite Cancer
    N-Methyl pemetrexed is an impurity of Pemetrexed. Pemetrexed is an antifolate cytotoxic agent that can be used for the research of cancer .
    N-Methyl pemetrexed
  • HY-130083
    Seco-Duocarmycin TM

    		ADC Payload DNA Alkylator/Crosslinker Cancer
    Seco-Duocarmycin TM is a DNA alkylator agent belonging to Duocarmycins family that inhibits DNA synthesis. Seco-Duocarmycin TM is a cytotoxic agent, used as the cytotoxic component in antibody-drug conjugates (ADC) [1].
    Seco-Duocarmycin TM
  • HY-135901
    Py-MPB-amino-C3-PBD

    		ADC Payload Bacterial Cancer
    Py-MPB-amino-C3-PBD is a cytotoxic agent comprised non-alkylating group. Py-MPB-amino-C3-PBD acts as the payload for ADCs. Antimicrobial activity .
    Py-MPB-amino-C3-PBD
  • HY-176495
    SG3683

    		DNA Alkylator/Crosslinker DNA/RNA Synthesis Cancer
    SG3683 is a DNA-targeted cytotoxic agent belonging to pyrrolobenzodiazepine (PBD) dimers. SG3683 exerts antitumor activity with an IC50 value of 0.74 nM in MDA-MB-436 cells. SG3683 is promising for research of cancers, such as breast cancer .
    SG3683
  • HY-135900
    Aniline-MPB-amino-C3-PBD

    		ADC Payload Bacterial Cancer
    Aniline-MPB-amino-C3-PBD is a cytotoxic agent comprised non-alkylating group. Aniline-MPB-amino-C3-PBD is a sequence-selective DNA minor-groove binding agent. Aniline-MPB-amino-C3-PBD acts as the payload for ADCs. Antimicrobial activity .
    Aniline-MPB-amino-C3-PBD
  • HY-121649
    AQ4

    		Topoisomerase Cancer
    AQ4 is a topoisomerase II inhibitor and DNA intercalator as a chemically stable cytotoxic agent in many human tumor lines .
    AQ4
  • HY-W091636
    3,3'-Azanediyldipropanoic acid

    3,3'-Iminodipropionic acid

    		 Biochemical Assay Reagents Others
    3,3'-Azanediyldipropanoic acid (3,3'-Iminodipropionic acid) can be used in preparation of linkers, lipids, and conjugates of cytotoxic agents.
    3,3'-Azanediyldipropanoic acid
  • HY-13640A
    Rabacfosadine succinate

    GS-9219 succinate; VDC-1101 succinate

    		 Nucleoside Antimetabolite/Analog Cancer
    Rabacfosadine (GS-9219) succinate, a novel proagent of the nucleotide analogue PMEG, is designed as a cytotoxic agent that preferentially targets lymphoid cells .
    Rabacfosadine succinate
  • HY-178774
    IP-DNQ

    Isopentyl-deoxynboquinone

    		 Quinone Reductase Cancer
    IP-DNQ is an efficient NQO1 dependent cytotoxic agent. IP-DNQ has a potent killing effect on MCF-7 cells (IC50 = 0.18 µM). IP-DNQ can be used for cancer research .
    IP-DNQ
  • HY-114249
    DFP-11207

    		Nucleoside Antimetabolite/Analog Dihydropyrimidine Dehydrogenase (DPD) Cancer
    DFP-11207 is an orally active fluoropyrimidine cytotoxic agent. DFP-11207 combines a 5-FU (HY-90006) pro-drug with a reversible DPD inhibitor and a potent inhibitor of OPRT, resulting in enhanced pharmacological activity of 5-FU with decreased gastrointestinal and myelosuppressive toxicities. DFP-11207 can be used for the research of cancer .
    DFP-11207
  • HY-128930
    6-O-2-Propyn-1-yl-D-galactose

    		ADC Linker Cancer
    6-O-2-Propyn-1-yl-D-galactose is a nonclaevable glycolinker for the functionalization of cytotoxic agents and applications in antibody-agent conjugation. 6-O-2-Propyn-1-yl-D-galactose is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    6-O-2-Propyn-1-yl-D-galactose
  • HY-N15600
    Merulidial

    (-)-Merulidial

    		 Antibiotic Fungal Bacterial DNA/RNA Synthesis Infection Cancer
    Merulidial (Compound 1) is an antibiotic and cytotoxic agent with a sesquiterpene dialdehyde structure. Merulidial significantly inhibits the germination of spores and the hyphal growth of the wood-roting basidiomycete Heterobasidion annosum (H. annosum) and the saprophytic mould Cladosporium cucumerinum (C.cucumerinum). Merulidial also inhibits a variety of bacteria, algae and DNA synthesis of ECA cells. Merulidial shows a strong anticancer activity with IC50 s of 20 and 10 μg/mL for ECA and L1210 cells, respectively .
    Merulidial
  • HY-P10775A
    BT1769 acetate

    		MMP Cancer
    BT1769 acetate is a conjugate and antitumor agent targeting MT1-MMP, with a Kd value of 3.35 nM against human targets. BT1769 acetate exhibits favorable pharmacokinetic properties. BT1769 acetate specifically binds to MT1-MMP via its bicyclic peptide component, delivering the cytotoxic agent MMAE (HY-15162) to antigen-expressing cells. It effectively inhibits tumor growth, induces complete responses, and significantly prolongs event-free survival in osteosarcoma patient-derived xenograft models. BT1769 acetate shows extremely low activity in Ewing sarcoma models and can be used in osteosarcoma-related research .
    BT1769 acetate
  • HY-126664
    Azonafide-PEABA

    		ADC Payload Cancer
    Azonafide-PEABA is a cytotoxic agent moiety .
    Azonafide-PEABA
  • HY-N14248
    Melithiazole A

    		Antibiotic Fungal Infection
    Melithiazol A is an antibiotic. Melithiazole A is a β-methoxyacrylate (MOA) inhibitor with strong anti-agent activity. Antifungal and cytotoxic agent .
    Melithiazole A
  • HY-16036A
    ALB-109564 hydrochloride

    12'-Methylthiovinblastine hydrochloride

    		 Microtubule/Tubulin Mitosis Cancer
    ALB-109564 (12'-Methylthiovinblastine) hydrochloride, a tubulin inhibitor, is a cytotoxic agent designed to kill cancer cells by disrupting mitosis .
    ALB-109564 hydrochloride
  • HY-N14249
    Melithiazole B

    		Antibiotic Fungal Infection
    Melithiazol B is an antibiotic. Melithiazole B is a β-methoxyacrylate (MOA) inhibitor with strong anti-agent activity. Antifungal and cytotoxic agent .
    Melithiazole B
  • HY-156860
    WP 1122

    		Drug Derivative Cancer
    WP 1122 is a 2-deoxy-D-glucose (HY-13966) analog that is a potent cytotoxic agent. WP 1122 is a glycolysis inhibitor. WP 1122 can be used for the research of cancer .
    WP 1122
  • HY-N10959
    4,15-Isoatriplicolide methylacrylate

    		Others Cancer
    4,15-Isoatriplicolide methylacrylate is a germacrane-type sesquiterpene lactone. 4,15-Isoatriplicolide methylacrylate also is a cytotoxic agent. 4,15-Isoatriplicolide methylacrylate has cytotoxic activity for MCF-7 human breast cancer cell line .
    4,15-Isoatriplicolide methylacrylate
  • HY-163918
    N,N-Dimethyl-idarubicin

    		P-glycoprotein Cancer
    N,N-Dimethyl-idarubicin, an Idarubicin (HY-17381) derivative, is a potent histone evictor which does not induce DNA double-strand breaks. N,N-Dimethyl-idarubicin, an anthracycline, is an effective cytotoxic agent for ABCB1-overexpressing, Doxorubicin-resistant cells .
    N,N-Dimethyl-idarubicin
  • HY-18981R
    Decursin (Standard)

    (+)-Decursin (Standard)

    		 Reference Standards PKC Apoptosis CXCR Neurological Disease Inflammation/Immunology Cancer
    Decursin (Standard) is the analytical standard of Decursin. This product is intended for research and analytical applications. Decursin ((+)-Decursin) is a potent anti-tumor agent. Decursin also is a cytotoxic agent and a potent protein kinase C activator. Decursin induces apoptosis and cell cycle arrest at G1 phase. Decursin decreases the expression of CDK2, CDK4, CDK6, cyclin D1 protein at 48 h. Decursin inhibits cell proliferation and migration. Decursin shows anti-tumor, anti-inflammatory and analgesic activities [4].
    Decursin (Standard)
  • HY-W017424R
    2-Aminobenzothiazole (Standard)

    		Reference Standards Apoptosis Drug Intermediate Caspase Others
    2-Aminobenzothiazole (Standard) is the analytical standard of 2-Aminobenzothiazole. This product is intended for research and analytical applications. 2-Aminobenzothiazole acts as a caspase 3/7 activator, an anticancer cytotoxic agent, and also exhibits neurotoxicity. 2-Aminobenzothiazole drives the apoptotic pathway by activating caspase 3/7, induces mitochondrial inner membrane depolarization, and triggers both early and late apoptosis via a caspase-dependent pathway. In zebrafish models, 2-Aminobenzothiazole induces oxidative damage in brain tissues and inhibits genes related to GABA and 5-HT synthesis pathways. Long-term exposure to 2-Aminobenzothiazole impairs motor ability, social behavior, anxiety-like state and cognitive function. 2-Aminobenzothiazole can be used in studies of human laryngeal carcinoma and related neurotoxicity .
    2-Aminobenzothiazole (Standard)
  • HY-N18115A
    Toosendansin A

    		Drug Derivative Cancer
    Toosendansin A is a salannin-type limonoid and cytotoxic agent found in the fruits of Melia azedarach. Toosendansin A can be used for the research of leukemia, stomach cancer, breast cancer .
    Toosendansin A
  • HY-Z9022
    Iso cephalomannine

    		Microtubule/Tubulin Cancer
    Iso cephalomannine is a tubulin-targeting cytotoxic agent. Iso cephalomannine induces cytotoxicity in breast cancer cells. Iso cephalomannine can be used in breast cancer-related research .
    Iso cephalomannine
  • HY-N17359
    Mulberrofuran W

    		Drug Derivative Cancer
    Mulberrofuran W is a 2-arylbenzofuran with a farnesyl group that exists in the root bark of Morus mongolica. It also acts as a cytotoxic agent with low cytotoxicity and weak tumor specificity .
    Mulberrofuran W
  • HY-141425
    NSC73306

    		P-glycoprotein Cancer
    NSC73306, a thiosemicarbazone, is a cell penetrant, cytotoxic agent that exhibits greater toxicity against cells expressing functional P-gp (P-glycoprotein) than against other cells .
    NSC73306
  • HY-122324A
    (-)-Tylophorine

    (-)-(R)-Tylophorine; (-)-DCB-3500; (-)-NSC-717335

    		 Others Cancer
    (-)-Tylophorine ((-)-(R)-Tylophorine) is a potent cytotoxic agent with activity against both drug-sensitive and multidrug-resistant cancer cell lines. (-)-Tylophorine has been explored in biomedical research for its anticancer applications .
    (-)-Tylophorine

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: